Immunocore Holdings: Strong International Growth and Promising Clinical Trials Drive Buy Recommendation

Analyst Tyler Van Buren from TD Cowen maintained a Buy rating on Immunocore Holdings (IMCR – Research Report) and keeping the price target at $60.00.

Tyler Van Buren has given his Buy rating due to a combination of factors, primarily driven by the strong performance and growth potential of Immunocore Holdings. The company’s flagship product, Kimmtrak, reported impressive sales figures, surpassing market expectations by 9%. This growth was largely fueled by international expansion, particularly in Europe, where demand has surged and new pricing agreements have been established.
Moreover, Immunocore is actively advancing its pipeline with ongoing trials, such as the TEBE-AM study for Kimmtrak in cutaneous melanoma, which could significantly increase the patient population it serves. The company’s strategic moves in expanding its market presence and the promising developments in its clinical trials underpin Van Buren’s optimistic outlook, reinforcing his Buy recommendation for the stock.